Publications

Publications

Filter Results: (79) Arrow Down

Show Results For

← Page 4 of 79 Results
  • 22 Sep 2008
  • Research & Ideas

The Silo Lives! Analyzing Coordination and Communication in Multiunit Companies

electronic communication data, one at a leading biopharmaceuticals company and a second at a global media and professional services firm. One of these follows senior leaders through a period of reorganization, and the other contains... View Details
Keywords: by Sarah Jane Gilbert
  • 24 Jun 2008
  • First Look

First Look: June 24, 2008

states. In a few cases—IT, biopharmaceuticals and communications equipment—where the total size of the cluster is small, and there is little historical legacy in Eastern Europe, the EU10 exhibits higher geographical concentration than... View Details
Keywords: Martha Lagace
  • 11 May 2010
  • First Look

First Look: May 11

rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark Levin moved the firm downstream away from... View Details
Keywords: Martha Lagace
  • 22 Aug 2006
  • First Look

First Look: August 22, 2006

805-067 Molecular Insight has developed a novel biopharmaceutical to detect heart attacks. The company's unique approach to intellectual property protection uses the Hatch Waxman Act and the Orphan Drug Act. The company is struggling to... View Details
Keywords: Martha Lagace
  • 16 Dec 2014
  • First Look

First Look: December 16

Stages of Innovation Through the lens of biopharmaceutical contract research organization (CRO) PAREXEL, this case traces the evolution of the firm as it reinvents itself in response to the transformation of the CRO sector from a small,... View Details
Keywords: Sean Silverthorne
  • 01 May 2007
  • First Look

First Look: May 1, 2007

question that has received less attention, however, is whether focus at the divisional level is complementary with, or a substitute for, focus at the firm level. We explore this question by considering the performance of investigative sites in View Details
Keywords: Sean Silverthorne
  • 18 Mar 2014
  • First Look

First Look: March 18

Robert, Carliss Y. Baldwin, Alan MacCormack, and David Dreyfus Abstract—In this paper, we test a method for visualizing and measuring software portfolio architectures and use our measures to predict the costs of architectural change. Our data is drawn from a View Details
Keywords: Sean Silverthorne
  • 11 Sep 2012
  • First Look

First Look: September 11

expansions of biopharmaceutical firms (by both new establishments and employment increase in existing establishments) in the U.S. in 1993-2005. We consider all activities in the value chain and allow location choices to vary by R&D,... View Details
Keywords: Sean Silverthorne
  • 27 Feb 2018
  • First Look

First Look at New Research and Ideas, February 27, 2018

company. Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/718403-PDF-ENG Harvard Business School Case 618-033 BeiGene BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity.... View Details
Keywords: Sean Silverthorne
  • 05 Dec 2017
  • First Look

First Look at New Research and Ideas, December 5, 2017

learning from parallel R&D projects in the setting of drug development. Leveraging the biopharmaceutical industry's unique characteristics to overcome barriers to measuring the project-level response to competitor news, I employ a... View Details
Keywords: Sean Silverthorne
  • 17 Aug 2010
  • First Look

First Look: August 17

companies increasingly are participants in open communities of science and technology. To participate in the system of exchange in such communities, firms often publicly disclose what would otherwise remain private discoveries. In a quantitative case study of one firm... View Details
Keywords: Martha Lagace
  • 17 Mar 2009
  • First Look

First Look: March 17, 2009

Agreements in Bio-Pharmaceuticals Authors:Juan Alcácer, John Cantwell, and Michelle Gittelman Publication:In Location of Biopharmaceutical Activity, edited by Iain M. Cockburn and Matthew J. Slaughter. NBER, forthcoming. Abstract As the... View Details
Keywords: Martha Lagace
  • 26 Apr 2011
  • Op-Ed

HBS Faculty Comment on Environmental Issues for Earth Day

Chicago press on June 1 in an edited volume entitled Accelerating Innovation: Insights from Multiple Sectors. In detailed histories of agriculture, chemicals, semiconductors, computers, the internet and biopharmaceuticals we asked "what... View Details
Keywords: by Staff; Energy; Utilities
  • 07 Feb 2017
  • First Look

First Look at New Research: February 7

from the Census Bureau's Longitudinal Business Database, we analyze the locations of new establishments of biopharmaceutical firms in the U.S. in 1993–2005. We consider all activities in the value chain and allow location choices to vary... View Details
Keywords: Sean Silverthorne
  • 14 Mar 2017
  • First Look

First Look at New Research, March 14

management consulting services for life science companies. By 2015, the company was expanding beyond the biopharmaceutical industry, offering analytical services to health care systems, like the National Health Service (NHS) in the United... View Details
Keywords: Sean Silverthorne
  • 16 Jul 2013
  • First Look

First Look: July 16

external structure between architectural components. Our test uses data from a biopharmaceutical company. In total, we analyzed 407 components and 1,157 dependencies. Results show that the enterprise structure can be classified as a... View Details
Keywords: Anna Secino
  • 12 Jul 2021
  • News

Alumni Confront the COVID-19 Crisis

world’s most pressing issues,” says Sarika Mendu (MBA 2020), one of founders. Damaris Skouras (MBA 1982) is founder, chairman, and CEO of Olatec Therapeutics, a biopharmaceutical firm. Olatec recently announced it is enrolling patients in... View Details
  • Web

Print View - Course Catalog

organizations that provide health care (e.g., hospitals, medical groups, retail clinics) or in firms that partner with, supply, consult to, or invest in such organizations (e.g., payers, biopharmaceutical and device companies, health... View Details